Trial Outcomes & Findings for Effects of Ghrelin on Alcohol Cue Reactivity and Craving (NCT NCT01190085)

NCT ID: NCT01190085

Last Updated: 2014-05-15

Results Overview

Whether ghrelin intravenous (i.v.), as compared to saline i.v., dose-dependently results in increased cue-reactivity (CR) responses to alcohol cues in terms of urge to drink \[as measured by the Alcohol Visual Analogue Scale (A-VAS)\]. The A-VAS was rated on 11-point anchored Likert-type scales, where 0 is the minimum score (no craving) and 11 is the maximum score (highest craving intensity). The change in the A-VAS score (deltaA-VAS) was used to indicate decrease (-d) or increase (+d) in craving intensity.

Recruitment status

COMPLETED

Study phase

Target enrollment

45 participants

Primary outcome timeframe

approximately 30 minutes after drug administration

Results posted on

2014-05-15

Participant Flow

Individuals were recruited via advertisements in local public transportation and mass-media

Participant milestones

Participant milestones
Measure	Ghrelin (1 Microg/kg) A 1 microg/kg dose of intravenous human acetylated ghrelin was administered once approximately 10 minutes before the start of the alcohol cue-reactivity experiment.	Ghrelin (3 Microg/kg) A 3 microg/kg dose of intravenous human acetylated ghrelin was administered once approximately 10 minutes before the start of the alcohol cue-reactivity experiment.	Saline Solution Intravenous saline solution (matched placebo) was administered once approximately 10 minutes before the start of the alcohol cue-reactivity experiment.
Overall Study STARTED	13	14	18
Overall Study COMPLETED	13	14	18
Overall Study NOT COMPLETED	0	0	0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Effects of Ghrelin on Alcohol Cue Reactivity and Craving

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Ghrelin (1 Microg/kg) n=13 Participants A 1 microg/kg dose of intravenous human acetylated ghrelin was administered once approximately 10 minutes before the start of the alcohol cue-reactivity experiment.	Ghrelin (3 Microg/kg) n=14 Participants A 3 microg/kg dose of intravenous human acetylated ghrelin was administered once approximately 10 minutes before the start of the alcohol cue-reactivity experiment.	Saline Solution n=18 Participants Intravenous saline solution (matched placebo) was administered once approximately 10 minutes before the start of the alcohol cue-reactivity experiment.	Total n=45 Participants Total of all reporting groups
Age, Categorical <=18 years	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants
Age, Categorical Between 18 and 65 years	13 Participants n=5 Participants	14 Participants n=7 Participants	18 Participants n=5 Participants	45 Participants n=4 Participants
Age, Categorical >=65 years	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants
Age, Continuous	42.8 years STANDARD_DEVIATION 9.8 • n=5 Participants	43.9 years STANDARD_DEVIATION 8.6 • n=7 Participants	46.6 years STANDARD_DEVIATION 9.0 • n=5 Participants	44.7 years STANDARD_DEVIATION 9.1 • n=4 Participants
Sex: Female, Male Female	4 Participants n=5 Participants	5 Participants n=7 Participants	7 Participants n=5 Participants	16 Participants n=4 Participants
Sex: Female, Male Male	9 Participants n=5 Participants	9 Participants n=7 Participants	11 Participants n=5 Participants	29 Participants n=4 Participants
Region of Enrollment United States	13 participants n=5 Participants	14 participants n=7 Participants	18 participants n=5 Participants	45 participants n=4 Participants

PRIMARY outcome

Timeframe: approximately 30 minutes after drug administration

Outcome measures

Outcome measures
Measure	Ghrelin (1 Microg/kg) n=13 Participants A 1 microg/kg dose of intravenous human acetylated ghrelin was administered once approximately 10 minutes before the start of the alcohol cue-reactivity experiment.	Ghrelin (3 Microg/kg) n=14 Participants A 3 microg/kg dose of intravenous human acetylated ghrelin was administered once approximately 10 minutes before the start of the alcohol cue-reactivity experiment.	Saline Solution n=18 Participants Intravenous saline solution (matched placebo) was administered once approximately 10 minutes before the start of the alcohol cue-reactivity experiment.
Alcohol Visual Analogue Scale (A-VAS)	1.95 units on a scale Standard Deviation 2.19	2.66 units on a scale Standard Deviation 2.19	4.29 units on a scale Standard Deviation 2.17

PRIMARY outcome

Timeframe: participants will be followed after the cue-reactivity experiment, an expected average of 7 days

Whether ghrelin intravenous (i.v.), as compared to saline i.v., does not significantly increase Adverse Events (AEs).

Outcome measures

Outcome measures
Measure	Ghrelin (1 Microg/kg) n=13 Participants A 1 microg/kg dose of intravenous human acetylated ghrelin was administered once approximately 10 minutes before the start of the alcohol cue-reactivity experiment.	Ghrelin (3 Microg/kg) n=14 Participants A 3 microg/kg dose of intravenous human acetylated ghrelin was administered once approximately 10 minutes before the start of the alcohol cue-reactivity experiment.	Saline Solution n=18 Participants Intravenous saline solution (matched placebo) was administered once approximately 10 minutes before the start of the alcohol cue-reactivity experiment.
Number of Participants With Adverse Events (AEs) as a Measure of Safety and Tolerability.	11 participants	12 participants	15 participants

PRIMARY outcome

Timeframe: approximately 30 minutes after drug administration

Whether ghrelin intravenous (i.v.), as compared to saline i.v., dose-dependently results in increased cue-reactivity (CR) responses to alcohol cues in terms of psychophysiological responses, namely salivation changes.

Outcome measures

Outcome measures
Measure	Ghrelin (1 Microg/kg) n=13 Participants A 1 microg/kg dose of intravenous human acetylated ghrelin was administered once approximately 10 minutes before the start of the alcohol cue-reactivity experiment.	Ghrelin (3 Microg/kg) n=14 Participants A 3 microg/kg dose of intravenous human acetylated ghrelin was administered once approximately 10 minutes before the start of the alcohol cue-reactivity experiment.	Saline Solution n=18 Participants Intravenous saline solution (matched placebo) was administered once approximately 10 minutes before the start of the alcohol cue-reactivity experiment.
Salivation	1.8 gram Standard Deviation 1.4	1.9 gram Standard Deviation 1.4	3.2 gram Standard Deviation 1.4

Adverse Events

Ghrelin (1 Microg/kg)

Serious events: 0 serious events

Other events: 11 other events

Deaths: 0 deaths

Ghrelin (3 Microg/kg)

Serious events: 0 serious events

Other events: 12 other events

Deaths: 0 deaths

Saline Solution

Serious events: 0 serious events

Other events: 15 other events

Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Additional Information

Dr. Lorenzo Leggio

Brown University

Phone: 401-863-1000

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee
Publication restrictions are in place

Other adverse events
Measure	Ghrelin (1 Microg/kg) n=13 participants at risk A 1 microg/kg dose of intravenous human acetylated ghrelin was administered once approximately 10 minutes before the start of the alcohol cue-reactivity experiment.	Ghrelin (3 Microg/kg) n=14 participants at risk A 3 microg/kg dose of intravenous human acetylated ghrelin was administered once approximately 10 minutes before the start of the alcohol cue-reactivity experiment.	Saline Solution n=18 participants at risk Intravenous saline solution (matched placebo) was administered once approximately 10 minutes before the start of the alcohol cue-reactivity experiment.
Cardiac disorders fast heart beat	0.00% 0/13 • Adverse events were collected +17 minutes and +29 minutes after the ghrelin/placebo administration was ended. The Systematic Assessment for Treatment Emergent Events (SAFTEE) was used for adverse events. For references, see: Levine J, Schooler NR (1986). Psychopharmacology bulletin. 22:343-381; and Johnson BA, Ait-Daoud N, Roache JD (2005). Journal of Studies on Alcohol Supplement.157-167; discussion 140.	0.00% 0/14 • Adverse events were collected +17 minutes and +29 minutes after the ghrelin/placebo administration was ended. The Systematic Assessment for Treatment Emergent Events (SAFTEE) was used for adverse events. For references, see: Levine J, Schooler NR (1986). Psychopharmacology bulletin. 22:343-381; and Johnson BA, Ait-Daoud N, Roache JD (2005). Journal of Studies on Alcohol Supplement.157-167; discussion 140.	5.6% 1/18 • Adverse events were collected +17 minutes and +29 minutes after the ghrelin/placebo administration was ended. The Systematic Assessment for Treatment Emergent Events (SAFTEE) was used for adverse events. For references, see: Levine J, Schooler NR (1986). Psychopharmacology bulletin. 22:343-381; and Johnson BA, Ait-Daoud N, Roache JD (2005). Journal of Studies on Alcohol Supplement.157-167; discussion 140.
Nervous system disorders Increase in appetite	61.5% 8/13 • Adverse events were collected +17 minutes and +29 minutes after the ghrelin/placebo administration was ended. The Systematic Assessment for Treatment Emergent Events (SAFTEE) was used for adverse events. For references, see: Levine J, Schooler NR (1986). Psychopharmacology bulletin. 22:343-381; and Johnson BA, Ait-Daoud N, Roache JD (2005). Journal of Studies on Alcohol Supplement.157-167; discussion 140.	78.6% 11/14 • Adverse events were collected +17 minutes and +29 minutes after the ghrelin/placebo administration was ended. The Systematic Assessment for Treatment Emergent Events (SAFTEE) was used for adverse events. For references, see: Levine J, Schooler NR (1986). Psychopharmacology bulletin. 22:343-381; and Johnson BA, Ait-Daoud N, Roache JD (2005). Journal of Studies on Alcohol Supplement.157-167; discussion 140.	44.4% 8/18 • Adverse events were collected +17 minutes and +29 minutes after the ghrelin/placebo administration was ended. The Systematic Assessment for Treatment Emergent Events (SAFTEE) was used for adverse events. For references, see: Levine J, Schooler NR (1986). Psychopharmacology bulletin. 22:343-381; and Johnson BA, Ait-Daoud N, Roache JD (2005). Journal of Studies on Alcohol Supplement.157-167; discussion 140.
Nervous system disorders Decrease in appetite	0.00% 0/13 • Adverse events were collected +17 minutes and +29 minutes after the ghrelin/placebo administration was ended. The Systematic Assessment for Treatment Emergent Events (SAFTEE) was used for adverse events. For references, see: Levine J, Schooler NR (1986). Psychopharmacology bulletin. 22:343-381; and Johnson BA, Ait-Daoud N, Roache JD (2005). Journal of Studies on Alcohol Supplement.157-167; discussion 140.	28.6% 4/14 • Adverse events were collected +17 minutes and +29 minutes after the ghrelin/placebo administration was ended. The Systematic Assessment for Treatment Emergent Events (SAFTEE) was used for adverse events. For references, see: Levine J, Schooler NR (1986). Psychopharmacology bulletin. 22:343-381; and Johnson BA, Ait-Daoud N, Roache JD (2005). Journal of Studies on Alcohol Supplement.157-167; discussion 140.	38.9% 7/18 • Adverse events were collected +17 minutes and +29 minutes after the ghrelin/placebo administration was ended. The Systematic Assessment for Treatment Emergent Events (SAFTEE) was used for adverse events. For references, see: Levine J, Schooler NR (1986). Psychopharmacology bulletin. 22:343-381; and Johnson BA, Ait-Daoud N, Roache JD (2005). Journal of Studies on Alcohol Supplement.157-167; discussion 140.
Nervous system disorders Dizziness	0.00% 0/13 • Adverse events were collected +17 minutes and +29 minutes after the ghrelin/placebo administration was ended. The Systematic Assessment for Treatment Emergent Events (SAFTEE) was used for adverse events. For references, see: Levine J, Schooler NR (1986). Psychopharmacology bulletin. 22:343-381; and Johnson BA, Ait-Daoud N, Roache JD (2005). Journal of Studies on Alcohol Supplement.157-167; discussion 140.	28.6% 4/14 • Adverse events were collected +17 minutes and +29 minutes after the ghrelin/placebo administration was ended. The Systematic Assessment for Treatment Emergent Events (SAFTEE) was used for adverse events. For references, see: Levine J, Schooler NR (1986). Psychopharmacology bulletin. 22:343-381; and Johnson BA, Ait-Daoud N, Roache JD (2005). Journal of Studies on Alcohol Supplement.157-167; discussion 140.	16.7% 3/18 • Adverse events were collected +17 minutes and +29 minutes after the ghrelin/placebo administration was ended. The Systematic Assessment for Treatment Emergent Events (SAFTEE) was used for adverse events. For references, see: Levine J, Schooler NR (1986). Psychopharmacology bulletin. 22:343-381; and Johnson BA, Ait-Daoud N, Roache JD (2005). Journal of Studies on Alcohol Supplement.157-167; discussion 140.
Eye disorders Changes in Vision	0.00% 0/13 • Adverse events were collected +17 minutes and +29 minutes after the ghrelin/placebo administration was ended. The Systematic Assessment for Treatment Emergent Events (SAFTEE) was used for adverse events. For references, see: Levine J, Schooler NR (1986). Psychopharmacology bulletin. 22:343-381; and Johnson BA, Ait-Daoud N, Roache JD (2005). Journal of Studies on Alcohol Supplement.157-167; discussion 140.	14.3% 2/14 • Adverse events were collected +17 minutes and +29 minutes after the ghrelin/placebo administration was ended. The Systematic Assessment for Treatment Emergent Events (SAFTEE) was used for adverse events. For references, see: Levine J, Schooler NR (1986). Psychopharmacology bulletin. 22:343-381; and Johnson BA, Ait-Daoud N, Roache JD (2005). Journal of Studies on Alcohol Supplement.157-167; discussion 140.	11.1% 2/18 • Adverse events were collected +17 minutes and +29 minutes after the ghrelin/placebo administration was ended. The Systematic Assessment for Treatment Emergent Events (SAFTEE) was used for adverse events. For references, see: Levine J, Schooler NR (1986). Psychopharmacology bulletin. 22:343-381; and Johnson BA, Ait-Daoud N, Roache JD (2005). Journal of Studies on Alcohol Supplement.157-167; discussion 140.
Nervous system disorders Sleepness	15.4% 2/13 • Adverse events were collected +17 minutes and +29 minutes after the ghrelin/placebo administration was ended. The Systematic Assessment for Treatment Emergent Events (SAFTEE) was used for adverse events. For references, see: Levine J, Schooler NR (1986). Psychopharmacology bulletin. 22:343-381; and Johnson BA, Ait-Daoud N, Roache JD (2005). Journal of Studies on Alcohol Supplement.157-167; discussion 140.	14.3% 2/14 • Adverse events were collected +17 minutes and +29 minutes after the ghrelin/placebo administration was ended. The Systematic Assessment for Treatment Emergent Events (SAFTEE) was used for adverse events. For references, see: Levine J, Schooler NR (1986). Psychopharmacology bulletin. 22:343-381; and Johnson BA, Ait-Daoud N, Roache JD (2005). Journal of Studies on Alcohol Supplement.157-167; discussion 140.	22.2% 4/18 • Adverse events were collected +17 minutes and +29 minutes after the ghrelin/placebo administration was ended. The Systematic Assessment for Treatment Emergent Events (SAFTEE) was used for adverse events. For references, see: Levine J, Schooler NR (1986). Psychopharmacology bulletin. 22:343-381; and Johnson BA, Ait-Daoud N, Roache JD (2005). Journal of Studies on Alcohol Supplement.157-167; discussion 140.
Nervous system disorders Fatigue	15.4% 2/13 • Adverse events were collected +17 minutes and +29 minutes after the ghrelin/placebo administration was ended. The Systematic Assessment for Treatment Emergent Events (SAFTEE) was used for adverse events. For references, see: Levine J, Schooler NR (1986). Psychopharmacology bulletin. 22:343-381; and Johnson BA, Ait-Daoud N, Roache JD (2005). Journal of Studies on Alcohol Supplement.157-167; discussion 140.	0.00% 0/14 • Adverse events were collected +17 minutes and +29 minutes after the ghrelin/placebo administration was ended. The Systematic Assessment for Treatment Emergent Events (SAFTEE) was used for adverse events. For references, see: Levine J, Schooler NR (1986). Psychopharmacology bulletin. 22:343-381; and Johnson BA, Ait-Daoud N, Roache JD (2005). Journal of Studies on Alcohol Supplement.157-167; discussion 140.	11.1% 2/18 • Adverse events were collected +17 minutes and +29 minutes after the ghrelin/placebo administration was ended. The Systematic Assessment for Treatment Emergent Events (SAFTEE) was used for adverse events. For references, see: Levine J, Schooler NR (1986). Psychopharmacology bulletin. 22:343-381; and Johnson BA, Ait-Daoud N, Roache JD (2005). Journal of Studies on Alcohol Supplement.157-167; discussion 140.
Nervous system disorders Difficulty with coordination	7.7% 1/13 • Adverse events were collected +17 minutes and +29 minutes after the ghrelin/placebo administration was ended. The Systematic Assessment for Treatment Emergent Events (SAFTEE) was used for adverse events. For references, see: Levine J, Schooler NR (1986). Psychopharmacology bulletin. 22:343-381; and Johnson BA, Ait-Daoud N, Roache JD (2005). Journal of Studies on Alcohol Supplement.157-167; discussion 140.	28.6% 4/14 • Adverse events were collected +17 minutes and +29 minutes after the ghrelin/placebo administration was ended. The Systematic Assessment for Treatment Emergent Events (SAFTEE) was used for adverse events. For references, see: Levine J, Schooler NR (1986). Psychopharmacology bulletin. 22:343-381; and Johnson BA, Ait-Daoud N, Roache JD (2005). Journal of Studies on Alcohol Supplement.157-167; discussion 140.	16.7% 3/18 • Adverse events were collected +17 minutes and +29 minutes after the ghrelin/placebo administration was ended. The Systematic Assessment for Treatment Emergent Events (SAFTEE) was used for adverse events. For references, see: Levine J, Schooler NR (1986). Psychopharmacology bulletin. 22:343-381; and Johnson BA, Ait-Daoud N, Roache JD (2005). Journal of Studies on Alcohol Supplement.157-167; discussion 140.
Nervous system disorders Difficulty with Concentration	0.00% 0/13 • Adverse events were collected +17 minutes and +29 minutes after the ghrelin/placebo administration was ended. The Systematic Assessment for Treatment Emergent Events (SAFTEE) was used for adverse events. For references, see: Levine J, Schooler NR (1986). Psychopharmacology bulletin. 22:343-381; and Johnson BA, Ait-Daoud N, Roache JD (2005). Journal of Studies on Alcohol Supplement.157-167; discussion 140.	0.00% 0/14 • Adverse events were collected +17 minutes and +29 minutes after the ghrelin/placebo administration was ended. The Systematic Assessment for Treatment Emergent Events (SAFTEE) was used for adverse events. For references, see: Levine J, Schooler NR (1986). Psychopharmacology bulletin. 22:343-381; and Johnson BA, Ait-Daoud N, Roache JD (2005). Journal of Studies on Alcohol Supplement.157-167; discussion 140.	5.6% 1/18 • Adverse events were collected +17 minutes and +29 minutes after the ghrelin/placebo administration was ended. The Systematic Assessment for Treatment Emergent Events (SAFTEE) was used for adverse events. For references, see: Levine J, Schooler NR (1986). Psychopharmacology bulletin. 22:343-381; and Johnson BA, Ait-Daoud N, Roache JD (2005). Journal of Studies on Alcohol Supplement.157-167; discussion 140.
Nervous system disorders Tingling in Fingers or Toes	7.7% 1/13 • Adverse events were collected +17 minutes and +29 minutes after the ghrelin/placebo administration was ended. The Systematic Assessment for Treatment Emergent Events (SAFTEE) was used for adverse events. For references, see: Levine J, Schooler NR (1986). Psychopharmacology bulletin. 22:343-381; and Johnson BA, Ait-Daoud N, Roache JD (2005). Journal of Studies on Alcohol Supplement.157-167; discussion 140.	0.00% 0/14 • Adverse events were collected +17 minutes and +29 minutes after the ghrelin/placebo administration was ended. The Systematic Assessment for Treatment Emergent Events (SAFTEE) was used for adverse events. For references, see: Levine J, Schooler NR (1986). Psychopharmacology bulletin. 22:343-381; and Johnson BA, Ait-Daoud N, Roache JD (2005). Journal of Studies on Alcohol Supplement.157-167; discussion 140.	11.1% 2/18 • Adverse events were collected +17 minutes and +29 minutes after the ghrelin/placebo administration was ended. The Systematic Assessment for Treatment Emergent Events (SAFTEE) was used for adverse events. For references, see: Levine J, Schooler NR (1986). Psychopharmacology bulletin. 22:343-381; and Johnson BA, Ait-Daoud N, Roache JD (2005). Journal of Studies on Alcohol Supplement.157-167; discussion 140.
Nervous system disorders Word finding Difficulties	0.00% 0/13 • Adverse events were collected +17 minutes and +29 minutes after the ghrelin/placebo administration was ended. The Systematic Assessment for Treatment Emergent Events (SAFTEE) was used for adverse events. For references, see: Levine J, Schooler NR (1986). Psychopharmacology bulletin. 22:343-381; and Johnson BA, Ait-Daoud N, Roache JD (2005). Journal of Studies on Alcohol Supplement.157-167; discussion 140.	0.00% 0/14 • Adverse events were collected +17 minutes and +29 minutes after the ghrelin/placebo administration was ended. The Systematic Assessment for Treatment Emergent Events (SAFTEE) was used for adverse events. For references, see: Levine J, Schooler NR (1986). Psychopharmacology bulletin. 22:343-381; and Johnson BA, Ait-Daoud N, Roache JD (2005). Journal of Studies on Alcohol Supplement.157-167; discussion 140.	11.1% 2/18 • Adverse events were collected +17 minutes and +29 minutes after the ghrelin/placebo administration was ended. The Systematic Assessment for Treatment Emergent Events (SAFTEE) was used for adverse events. For references, see: Levine J, Schooler NR (1986). Psychopharmacology bulletin. 22:343-381; and Johnson BA, Ait-Daoud N, Roache JD (2005). Journal of Studies on Alcohol Supplement.157-167; discussion 140.
Nervous system disorders Memory Difficulties	0.00% 0/13 • Adverse events were collected +17 minutes and +29 minutes after the ghrelin/placebo administration was ended. The Systematic Assessment for Treatment Emergent Events (SAFTEE) was used for adverse events. For references, see: Levine J, Schooler NR (1986). Psychopharmacology bulletin. 22:343-381; and Johnson BA, Ait-Daoud N, Roache JD (2005). Journal of Studies on Alcohol Supplement.157-167; discussion 140.	0.00% 0/14 • Adverse events were collected +17 minutes and +29 minutes after the ghrelin/placebo administration was ended. The Systematic Assessment for Treatment Emergent Events (SAFTEE) was used for adverse events. For references, see: Levine J, Schooler NR (1986). Psychopharmacology bulletin. 22:343-381; and Johnson BA, Ait-Daoud N, Roache JD (2005). Journal of Studies on Alcohol Supplement.157-167; discussion 140.	16.7% 3/18 • Adverse events were collected +17 minutes and +29 minutes after the ghrelin/placebo administration was ended. The Systematic Assessment for Treatment Emergent Events (SAFTEE) was used for adverse events. For references, see: Levine J, Schooler NR (1986). Psychopharmacology bulletin. 22:343-381; and Johnson BA, Ait-Daoud N, Roache JD (2005). Journal of Studies on Alcohol Supplement.157-167; discussion 140.
Nervous system disorders Change in Taste	7.7% 1/13 • Adverse events were collected +17 minutes and +29 minutes after the ghrelin/placebo administration was ended. The Systematic Assessment for Treatment Emergent Events (SAFTEE) was used for adverse events. For references, see: Levine J, Schooler NR (1986). Psychopharmacology bulletin. 22:343-381; and Johnson BA, Ait-Daoud N, Roache JD (2005). Journal of Studies on Alcohol Supplement.157-167; discussion 140.	7.1% 1/14 • Adverse events were collected +17 minutes and +29 minutes after the ghrelin/placebo administration was ended. The Systematic Assessment for Treatment Emergent Events (SAFTEE) was used for adverse events. For references, see: Levine J, Schooler NR (1986). Psychopharmacology bulletin. 22:343-381; and Johnson BA, Ait-Daoud N, Roache JD (2005). Journal of Studies on Alcohol Supplement.157-167; discussion 140.	11.1% 2/18 • Adverse events were collected +17 minutes and +29 minutes after the ghrelin/placebo administration was ended. The Systematic Assessment for Treatment Emergent Events (SAFTEE) was used for adverse events. For references, see: Levine J, Schooler NR (1986). Psychopharmacology bulletin. 22:343-381; and Johnson BA, Ait-Daoud N, Roache JD (2005). Journal of Studies on Alcohol Supplement.157-167; discussion 140.
Nervous system disorders Tremor	7.7% 1/13 • Adverse events were collected +17 minutes and +29 minutes after the ghrelin/placebo administration was ended. The Systematic Assessment for Treatment Emergent Events (SAFTEE) was used for adverse events. For references, see: Levine J, Schooler NR (1986). Psychopharmacology bulletin. 22:343-381; and Johnson BA, Ait-Daoud N, Roache JD (2005). Journal of Studies on Alcohol Supplement.157-167; discussion 140.	21.4% 3/14 • Adverse events were collected +17 minutes and +29 minutes after the ghrelin/placebo administration was ended. The Systematic Assessment for Treatment Emergent Events (SAFTEE) was used for adverse events. For references, see: Levine J, Schooler NR (1986). Psychopharmacology bulletin. 22:343-381; and Johnson BA, Ait-Daoud N, Roache JD (2005). Journal of Studies on Alcohol Supplement.157-167; discussion 140.	22.2% 4/18 • Adverse events were collected +17 minutes and +29 minutes after the ghrelin/placebo administration was ended. The Systematic Assessment for Treatment Emergent Events (SAFTEE) was used for adverse events. For references, see: Levine J, Schooler NR (1986). Psychopharmacology bulletin. 22:343-381; and Johnson BA, Ait-Daoud N, Roache JD (2005). Journal of Studies on Alcohol Supplement.157-167; discussion 140.
Gastrointestinal disorders Constipation	0.00% 0/13 • Adverse events were collected +17 minutes and +29 minutes after the ghrelin/placebo administration was ended. The Systematic Assessment for Treatment Emergent Events (SAFTEE) was used for adverse events. For references, see: Levine J, Schooler NR (1986). Psychopharmacology bulletin. 22:343-381; and Johnson BA, Ait-Daoud N, Roache JD (2005). Journal of Studies on Alcohol Supplement.157-167; discussion 140.	7.1% 1/14 • Adverse events were collected +17 minutes and +29 minutes after the ghrelin/placebo administration was ended. The Systematic Assessment for Treatment Emergent Events (SAFTEE) was used for adverse events. For references, see: Levine J, Schooler NR (1986). Psychopharmacology bulletin. 22:343-381; and Johnson BA, Ait-Daoud N, Roache JD (2005). Journal of Studies on Alcohol Supplement.157-167; discussion 140.	5.6% 1/18 • Adverse events were collected +17 minutes and +29 minutes after the ghrelin/placebo administration was ended. The Systematic Assessment for Treatment Emergent Events (SAFTEE) was used for adverse events. For references, see: Levine J, Schooler NR (1986). Psychopharmacology bulletin. 22:343-381; and Johnson BA, Ait-Daoud N, Roache JD (2005). Journal of Studies on Alcohol Supplement.157-167; discussion 140.
Gastrointestinal disorders Diarrhea	0.00% 0/13 • Adverse events were collected +17 minutes and +29 minutes after the ghrelin/placebo administration was ended. The Systematic Assessment for Treatment Emergent Events (SAFTEE) was used for adverse events. For references, see: Levine J, Schooler NR (1986). Psychopharmacology bulletin. 22:343-381; and Johnson BA, Ait-Daoud N, Roache JD (2005). Journal of Studies on Alcohol Supplement.157-167; discussion 140.	0.00% 0/14 • Adverse events were collected +17 minutes and +29 minutes after the ghrelin/placebo administration was ended. The Systematic Assessment for Treatment Emergent Events (SAFTEE) was used for adverse events. For references, see: Levine J, Schooler NR (1986). Psychopharmacology bulletin. 22:343-381; and Johnson BA, Ait-Daoud N, Roache JD (2005). Journal of Studies on Alcohol Supplement.157-167; discussion 140.	5.6% 1/18 • Adverse events were collected +17 minutes and +29 minutes after the ghrelin/placebo administration was ended. The Systematic Assessment for Treatment Emergent Events (SAFTEE) was used for adverse events. For references, see: Levine J, Schooler NR (1986). Psychopharmacology bulletin. 22:343-381; and Johnson BA, Ait-Daoud N, Roache JD (2005). Journal of Studies on Alcohol Supplement.157-167; discussion 140.
Gastrointestinal disorders Nausea	0.00% 0/13 • Adverse events were collected +17 minutes and +29 minutes after the ghrelin/placebo administration was ended. The Systematic Assessment for Treatment Emergent Events (SAFTEE) was used for adverse events. For references, see: Levine J, Schooler NR (1986). Psychopharmacology bulletin. 22:343-381; and Johnson BA, Ait-Daoud N, Roache JD (2005). Journal of Studies on Alcohol Supplement.157-167; discussion 140.	0.00% 0/14 • Adverse events were collected +17 minutes and +29 minutes after the ghrelin/placebo administration was ended. The Systematic Assessment for Treatment Emergent Events (SAFTEE) was used for adverse events. For references, see: Levine J, Schooler NR (1986). Psychopharmacology bulletin. 22:343-381; and Johnson BA, Ait-Daoud N, Roache JD (2005). Journal of Studies on Alcohol Supplement.157-167; discussion 140.	5.6% 1/18 • Adverse events were collected +17 minutes and +29 minutes after the ghrelin/placebo administration was ended. The Systematic Assessment for Treatment Emergent Events (SAFTEE) was used for adverse events. For references, see: Levine J, Schooler NR (1986). Psychopharmacology bulletin. 22:343-381; and Johnson BA, Ait-Daoud N, Roache JD (2005). Journal of Studies on Alcohol Supplement.157-167; discussion 140.
Nervous system disorders Headache	0.00% 0/13 • Adverse events were collected +17 minutes and +29 minutes after the ghrelin/placebo administration was ended. The Systematic Assessment for Treatment Emergent Events (SAFTEE) was used for adverse events. For references, see: Levine J, Schooler NR (1986). Psychopharmacology bulletin. 22:343-381; and Johnson BA, Ait-Daoud N, Roache JD (2005). Journal of Studies on Alcohol Supplement.157-167; discussion 140.	0.00% 0/14 • Adverse events were collected +17 minutes and +29 minutes after the ghrelin/placebo administration was ended. The Systematic Assessment for Treatment Emergent Events (SAFTEE) was used for adverse events. For references, see: Levine J, Schooler NR (1986). Psychopharmacology bulletin. 22:343-381; and Johnson BA, Ait-Daoud N, Roache JD (2005). Journal of Studies on Alcohol Supplement.157-167; discussion 140.	11.1% 2/18 • Adverse events were collected +17 minutes and +29 minutes after the ghrelin/placebo administration was ended. The Systematic Assessment for Treatment Emergent Events (SAFTEE) was used for adverse events. For references, see: Levine J, Schooler NR (1986). Psychopharmacology bulletin. 22:343-381; and Johnson BA, Ait-Daoud N, Roache JD (2005). Journal of Studies on Alcohol Supplement.157-167; discussion 140.
Nervous system disorders Restlessness	15.4% 2/13 • Adverse events were collected +17 minutes and +29 minutes after the ghrelin/placebo administration was ended. The Systematic Assessment for Treatment Emergent Events (SAFTEE) was used for adverse events. For references, see: Levine J, Schooler NR (1986). Psychopharmacology bulletin. 22:343-381; and Johnson BA, Ait-Daoud N, Roache JD (2005). Journal of Studies on Alcohol Supplement.157-167; discussion 140.	7.1% 1/14 • Adverse events were collected +17 minutes and +29 minutes after the ghrelin/placebo administration was ended. The Systematic Assessment for Treatment Emergent Events (SAFTEE) was used for adverse events. For references, see: Levine J, Schooler NR (1986). Psychopharmacology bulletin. 22:343-381; and Johnson BA, Ait-Daoud N, Roache JD (2005). Journal of Studies on Alcohol Supplement.157-167; discussion 140.	38.9% 7/18 • Adverse events were collected +17 minutes and +29 minutes after the ghrelin/placebo administration was ended. The Systematic Assessment for Treatment Emergent Events (SAFTEE) was used for adverse events. For references, see: Levine J, Schooler NR (1986). Psychopharmacology bulletin. 22:343-381; and Johnson BA, Ait-Daoud N, Roache JD (2005). Journal of Studies on Alcohol Supplement.157-167; discussion 140.
Psychiatric disorders Anxiety	53.8% 7/13 • Adverse events were collected +17 minutes and +29 minutes after the ghrelin/placebo administration was ended. The Systematic Assessment for Treatment Emergent Events (SAFTEE) was used for adverse events. For references, see: Levine J, Schooler NR (1986). Psychopharmacology bulletin. 22:343-381; and Johnson BA, Ait-Daoud N, Roache JD (2005). Journal of Studies on Alcohol Supplement.157-167; discussion 140.	14.3% 2/14 • Adverse events were collected +17 minutes and +29 minutes after the ghrelin/placebo administration was ended. The Systematic Assessment for Treatment Emergent Events (SAFTEE) was used for adverse events. For references, see: Levine J, Schooler NR (1986). Psychopharmacology bulletin. 22:343-381; and Johnson BA, Ait-Daoud N, Roache JD (2005). Journal of Studies on Alcohol Supplement.157-167; discussion 140.	22.2% 4/18 • Adverse events were collected +17 minutes and +29 minutes after the ghrelin/placebo administration was ended. The Systematic Assessment for Treatment Emergent Events (SAFTEE) was used for adverse events. For references, see: Levine J, Schooler NR (1986). Psychopharmacology bulletin. 22:343-381; and Johnson BA, Ait-Daoud N, Roache JD (2005). Journal of Studies on Alcohol Supplement.157-167; discussion 140.
Nervous system disorders Irritability	7.7% 1/13 • Adverse events were collected +17 minutes and +29 minutes after the ghrelin/placebo administration was ended. The Systematic Assessment for Treatment Emergent Events (SAFTEE) was used for adverse events. For references, see: Levine J, Schooler NR (1986). Psychopharmacology bulletin. 22:343-381; and Johnson BA, Ait-Daoud N, Roache JD (2005). Journal of Studies on Alcohol Supplement.157-167; discussion 140.	7.1% 1/14 • Adverse events were collected +17 minutes and +29 minutes after the ghrelin/placebo administration was ended. The Systematic Assessment for Treatment Emergent Events (SAFTEE) was used for adverse events. For references, see: Levine J, Schooler NR (1986). Psychopharmacology bulletin. 22:343-381; and Johnson BA, Ait-Daoud N, Roache JD (2005). Journal of Studies on Alcohol Supplement.157-167; discussion 140.	11.1% 2/18 • Adverse events were collected +17 minutes and +29 minutes after the ghrelin/placebo administration was ended. The Systematic Assessment for Treatment Emergent Events (SAFTEE) was used for adverse events. For references, see: Levine J, Schooler NR (1986). Psychopharmacology bulletin. 22:343-381; and Johnson BA, Ait-Daoud N, Roache JD (2005). Journal of Studies on Alcohol Supplement.157-167; discussion 140.
Psychiatric disorders Mood Disturbance	0.00% 0/13 • Adverse events were collected +17 minutes and +29 minutes after the ghrelin/placebo administration was ended. The Systematic Assessment for Treatment Emergent Events (SAFTEE) was used for adverse events. For references, see: Levine J, Schooler NR (1986). Psychopharmacology bulletin. 22:343-381; and Johnson BA, Ait-Daoud N, Roache JD (2005). Journal of Studies on Alcohol Supplement.157-167; discussion 140.	21.4% 3/14 • Adverse events were collected +17 minutes and +29 minutes after the ghrelin/placebo administration was ended. The Systematic Assessment for Treatment Emergent Events (SAFTEE) was used for adverse events. For references, see: Levine J, Schooler NR (1986). Psychopharmacology bulletin. 22:343-381; and Johnson BA, Ait-Daoud N, Roache JD (2005). Journal of Studies on Alcohol Supplement.157-167; discussion 140.	27.8% 5/18 • Adverse events were collected +17 minutes and +29 minutes after the ghrelin/placebo administration was ended. The Systematic Assessment for Treatment Emergent Events (SAFTEE) was used for adverse events. For references, see: Levine J, Schooler NR (1986). Psychopharmacology bulletin. 22:343-381; and Johnson BA, Ait-Daoud N, Roache JD (2005). Journal of Studies on Alcohol Supplement.157-167; discussion 140.
Nervous system disorders Confusion	0.00% 0/13 • Adverse events were collected +17 minutes and +29 minutes after the ghrelin/placebo administration was ended. The Systematic Assessment for Treatment Emergent Events (SAFTEE) was used for adverse events. For references, see: Levine J, Schooler NR (1986). Psychopharmacology bulletin. 22:343-381; and Johnson BA, Ait-Daoud N, Roache JD (2005). Journal of Studies on Alcohol Supplement.157-167; discussion 140.	7.1% 1/14 • Adverse events were collected +17 minutes and +29 minutes after the ghrelin/placebo administration was ended. The Systematic Assessment for Treatment Emergent Events (SAFTEE) was used for adverse events. For references, see: Levine J, Schooler NR (1986). Psychopharmacology bulletin. 22:343-381; and Johnson BA, Ait-Daoud N, Roache JD (2005). Journal of Studies on Alcohol Supplement.157-167; discussion 140.	11.1% 2/18 • Adverse events were collected +17 minutes and +29 minutes after the ghrelin/placebo administration was ended. The Systematic Assessment for Treatment Emergent Events (SAFTEE) was used for adverse events. For references, see: Levine J, Schooler NR (1986). Psychopharmacology bulletin. 22:343-381; and Johnson BA, Ait-Daoud N, Roache JD (2005). Journal of Studies on Alcohol Supplement.157-167; discussion 140.
Reproductive system and breast disorders Changes in Libido	0.00% 0/13 • Adverse events were collected +17 minutes and +29 minutes after the ghrelin/placebo administration was ended. The Systematic Assessment for Treatment Emergent Events (SAFTEE) was used for adverse events. For references, see: Levine J, Schooler NR (1986). Psychopharmacology bulletin. 22:343-381; and Johnson BA, Ait-Daoud N, Roache JD (2005). Journal of Studies on Alcohol Supplement.157-167; discussion 140.	0.00% 0/14 • Adverse events were collected +17 minutes and +29 minutes after the ghrelin/placebo administration was ended. The Systematic Assessment for Treatment Emergent Events (SAFTEE) was used for adverse events. For references, see: Levine J, Schooler NR (1986). Psychopharmacology bulletin. 22:343-381; and Johnson BA, Ait-Daoud N, Roache JD (2005). Journal of Studies on Alcohol Supplement.157-167; discussion 140.	16.7% 3/18 • Adverse events were collected +17 minutes and +29 minutes after the ghrelin/placebo administration was ended. The Systematic Assessment for Treatment Emergent Events (SAFTEE) was used for adverse events. For references, see: Levine J, Schooler NR (1986). Psychopharmacology bulletin. 22:343-381; and Johnson BA, Ait-Daoud N, Roache JD (2005). Journal of Studies on Alcohol Supplement.157-167; discussion 140.
Respiratory, thoracic and mediastinal disorders Slowed Breathing	0.00% 0/13 • Adverse events were collected +17 minutes and +29 minutes after the ghrelin/placebo administration was ended. The Systematic Assessment for Treatment Emergent Events (SAFTEE) was used for adverse events. For references, see: Levine J, Schooler NR (1986). Psychopharmacology bulletin. 22:343-381; and Johnson BA, Ait-Daoud N, Roache JD (2005). Journal of Studies on Alcohol Supplement.157-167; discussion 140.	7.1% 1/14 • Adverse events were collected +17 minutes and +29 minutes after the ghrelin/placebo administration was ended. The Systematic Assessment for Treatment Emergent Events (SAFTEE) was used for adverse events. For references, see: Levine J, Schooler NR (1986). Psychopharmacology bulletin. 22:343-381; and Johnson BA, Ait-Daoud N, Roache JD (2005). Journal of Studies on Alcohol Supplement.157-167; discussion 140.	11.1% 2/18 • Adverse events were collected +17 minutes and +29 minutes after the ghrelin/placebo administration was ended. The Systematic Assessment for Treatment Emergent Events (SAFTEE) was used for adverse events. For references, see: Levine J, Schooler NR (1986). Psychopharmacology bulletin. 22:343-381; and Johnson BA, Ait-Daoud N, Roache JD (2005). Journal of Studies on Alcohol Supplement.157-167; discussion 140.
Respiratory, thoracic and mediastinal disorders Difficulty breathing	7.7% 1/13 • Adverse events were collected +17 minutes and +29 minutes after the ghrelin/placebo administration was ended. The Systematic Assessment for Treatment Emergent Events (SAFTEE) was used for adverse events. For references, see: Levine J, Schooler NR (1986). Psychopharmacology bulletin. 22:343-381; and Johnson BA, Ait-Daoud N, Roache JD (2005). Journal of Studies on Alcohol Supplement.157-167; discussion 140.	0.00% 0/14 • Adverse events were collected +17 minutes and +29 minutes after the ghrelin/placebo administration was ended. The Systematic Assessment for Treatment Emergent Events (SAFTEE) was used for adverse events. For references, see: Levine J, Schooler NR (1986). Psychopharmacology bulletin. 22:343-381; and Johnson BA, Ait-Daoud N, Roache JD (2005). Journal of Studies on Alcohol Supplement.157-167; discussion 140.	5.6% 1/18 • Adverse events were collected +17 minutes and +29 minutes after the ghrelin/placebo administration was ended. The Systematic Assessment for Treatment Emergent Events (SAFTEE) was used for adverse events. For references, see: Levine J, Schooler NR (1986). Psychopharmacology bulletin. 22:343-381; and Johnson BA, Ait-Daoud N, Roache JD (2005). Journal of Studies on Alcohol Supplement.157-167; discussion 140.
Respiratory, thoracic and mediastinal disorders Swelling of throat or tongue	0.00% 0/13 • Adverse events were collected +17 minutes and +29 minutes after the ghrelin/placebo administration was ended. The Systematic Assessment for Treatment Emergent Events (SAFTEE) was used for adverse events. For references, see: Levine J, Schooler NR (1986). Psychopharmacology bulletin. 22:343-381; and Johnson BA, Ait-Daoud N, Roache JD (2005). Journal of Studies on Alcohol Supplement.157-167; discussion 140.	7.1% 1/14 • Adverse events were collected +17 minutes and +29 minutes after the ghrelin/placebo administration was ended. The Systematic Assessment for Treatment Emergent Events (SAFTEE) was used for adverse events. For references, see: Levine J, Schooler NR (1986). Psychopharmacology bulletin. 22:343-381; and Johnson BA, Ait-Daoud N, Roache JD (2005). Journal of Studies on Alcohol Supplement.157-167; discussion 140.	5.6% 1/18 • Adverse events were collected +17 minutes and +29 minutes after the ghrelin/placebo administration was ended. The Systematic Assessment for Treatment Emergent Events (SAFTEE) was used for adverse events. For references, see: Levine J, Schooler NR (1986). Psychopharmacology bulletin. 22:343-381; and Johnson BA, Ait-Daoud N, Roache JD (2005). Journal of Studies on Alcohol Supplement.157-167; discussion 140.
Skin and subcutaneous tissue disorders itching	0.00% 0/13 • Adverse events were collected +17 minutes and +29 minutes after the ghrelin/placebo administration was ended. The Systematic Assessment for Treatment Emergent Events (SAFTEE) was used for adverse events. For references, see: Levine J, Schooler NR (1986). Psychopharmacology bulletin. 22:343-381; and Johnson BA, Ait-Daoud N, Roache JD (2005). Journal of Studies on Alcohol Supplement.157-167; discussion 140.	0.00% 0/14 • Adverse events were collected +17 minutes and +29 minutes after the ghrelin/placebo administration was ended. The Systematic Assessment for Treatment Emergent Events (SAFTEE) was used for adverse events. For references, see: Levine J, Schooler NR (1986). Psychopharmacology bulletin. 22:343-381; and Johnson BA, Ait-Daoud N, Roache JD (2005). Journal of Studies on Alcohol Supplement.157-167; discussion 140.	11.1% 2/18 • Adverse events were collected +17 minutes and +29 minutes after the ghrelin/placebo administration was ended. The Systematic Assessment for Treatment Emergent Events (SAFTEE) was used for adverse events. For references, see: Levine J, Schooler NR (1986). Psychopharmacology bulletin. 22:343-381; and Johnson BA, Ait-Daoud N, Roache JD (2005). Journal of Studies on Alcohol Supplement.157-167; discussion 140.
Renal and urinary disorders Difficulty passing urine	0.00% 0/13 • Adverse events were collected +17 minutes and +29 minutes after the ghrelin/placebo administration was ended. The Systematic Assessment for Treatment Emergent Events (SAFTEE) was used for adverse events. For references, see: Levine J, Schooler NR (1986). Psychopharmacology bulletin. 22:343-381; and Johnson BA, Ait-Daoud N, Roache JD (2005). Journal of Studies on Alcohol Supplement.157-167; discussion 140.	0.00% 0/14 • Adverse events were collected +17 minutes and +29 minutes after the ghrelin/placebo administration was ended. The Systematic Assessment for Treatment Emergent Events (SAFTEE) was used for adverse events. For references, see: Levine J, Schooler NR (1986). Psychopharmacology bulletin. 22:343-381; and Johnson BA, Ait-Daoud N, Roache JD (2005). Journal of Studies on Alcohol Supplement.157-167; discussion 140.	5.6% 1/18 • Adverse events were collected +17 minutes and +29 minutes after the ghrelin/placebo administration was ended. The Systematic Assessment for Treatment Emergent Events (SAFTEE) was used for adverse events. For references, see: Levine J, Schooler NR (1986). Psychopharmacology bulletin. 22:343-381; and Johnson BA, Ait-Daoud N, Roache JD (2005). Journal of Studies on Alcohol Supplement.157-167; discussion 140.
Musculoskeletal and connective tissue disorders Muscle aches	0.00% 0/13 • Adverse events were collected +17 minutes and +29 minutes after the ghrelin/placebo administration was ended. The Systematic Assessment for Treatment Emergent Events (SAFTEE) was used for adverse events. For references, see: Levine J, Schooler NR (1986). Psychopharmacology bulletin. 22:343-381; and Johnson BA, Ait-Daoud N, Roache JD (2005). Journal of Studies on Alcohol Supplement.157-167; discussion 140.	0.00% 0/14 • Adverse events were collected +17 minutes and +29 minutes after the ghrelin/placebo administration was ended. The Systematic Assessment for Treatment Emergent Events (SAFTEE) was used for adverse events. For references, see: Levine J, Schooler NR (1986). Psychopharmacology bulletin. 22:343-381; and Johnson BA, Ait-Daoud N, Roache JD (2005). Journal of Studies on Alcohol Supplement.157-167; discussion 140.	22.2% 4/18 • Adverse events were collected +17 minutes and +29 minutes after the ghrelin/placebo administration was ended. The Systematic Assessment for Treatment Emergent Events (SAFTEE) was used for adverse events. For references, see: Levine J, Schooler NR (1986). Psychopharmacology bulletin. 22:343-381; and Johnson BA, Ait-Daoud N, Roache JD (2005). Journal of Studies on Alcohol Supplement.157-167; discussion 140.
Eye disorders eye pain	0.00% 0/13 • Adverse events were collected +17 minutes and +29 minutes after the ghrelin/placebo administration was ended. The Systematic Assessment for Treatment Emergent Events (SAFTEE) was used for adverse events. For references, see: Levine J, Schooler NR (1986). Psychopharmacology bulletin. 22:343-381; and Johnson BA, Ait-Daoud N, Roache JD (2005). Journal of Studies on Alcohol Supplement.157-167; discussion 140.	0.00% 0/14 • Adverse events were collected +17 minutes and +29 minutes after the ghrelin/placebo administration was ended. The Systematic Assessment for Treatment Emergent Events (SAFTEE) was used for adverse events. For references, see: Levine J, Schooler NR (1986). Psychopharmacology bulletin. 22:343-381; and Johnson BA, Ait-Daoud N, Roache JD (2005). Journal of Studies on Alcohol Supplement.157-167; discussion 140.	11.1% 2/18 • Adverse events were collected +17 minutes and +29 minutes after the ghrelin/placebo administration was ended. The Systematic Assessment for Treatment Emergent Events (SAFTEE) was used for adverse events. For references, see: Levine J, Schooler NR (1986). Psychopharmacology bulletin. 22:343-381; and Johnson BA, Ait-Daoud N, Roache JD (2005). Journal of Studies on Alcohol Supplement.157-167; discussion 140.
General disorders Decreased sweating	0.00% 0/13 • Adverse events were collected +17 minutes and +29 minutes after the ghrelin/placebo administration was ended. The Systematic Assessment for Treatment Emergent Events (SAFTEE) was used for adverse events. For references, see: Levine J, Schooler NR (1986). Psychopharmacology bulletin. 22:343-381; and Johnson BA, Ait-Daoud N, Roache JD (2005). Journal of Studies on Alcohol Supplement.157-167; discussion 140.	0.00% 0/14 • Adverse events were collected +17 minutes and +29 minutes after the ghrelin/placebo administration was ended. The Systematic Assessment for Treatment Emergent Events (SAFTEE) was used for adverse events. For references, see: Levine J, Schooler NR (1986). Psychopharmacology bulletin. 22:343-381; and Johnson BA, Ait-Daoud N, Roache JD (2005). Journal of Studies on Alcohol Supplement.157-167; discussion 140.	5.6% 1/18 • Adverse events were collected +17 minutes and +29 minutes after the ghrelin/placebo administration was ended. The Systematic Assessment for Treatment Emergent Events (SAFTEE) was used for adverse events. For references, see: Levine J, Schooler NR (1986). Psychopharmacology bulletin. 22:343-381; and Johnson BA, Ait-Daoud N, Roache JD (2005). Journal of Studies on Alcohol Supplement.157-167; discussion 140.